Heptavalent botulism antitoxin

The Heptavalent Botulism AntiToxin – HBAT, made by Cangene Corporation – is a licensed, commercially available botulism anti-toxin that effectively neutralizes all seven known botulinum nerve toxin serotypes (types A, B, C, D, E, F and G). It is indicated for sporadic cases of life-threatening botulism and is also stockpiled for the eventuality of botulinum nerve toxins being used in a future bioterrorist attack.

HBAT was approved in 2010 by the CDC for the indication of treating naturally occurring non-infant botulism on an investigational basis, replacing two earlier products. It was licensed for commercial marketing by the FDA in 2013.

HBAT was developed from equine (horse) plasma at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The main funding stream was the Biomedical Advanced Research and Development Authority (within the US Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response). It was then available for many years on an IND (investigational) basis from the US Centers for Disease Control and Prevention (CDC).

On June 1, 2006, the DHHS awarded a $363 million contract to Cangene Corporation for 200,000 doses of HBAT over five years for delivery into the US (SNS). The CDC began supplying doses to the SNS in 2007 under a now $427 million contract with the DHHS, according to a Cangene press release. In 2010, the CDC replaced the licensed bivalent botulinum antitoxin AB (BAT-AB, or “BabyBIG”) and the investigational monovalent botulinum antitoxin E (BAT-E) with HBAT when the former two products indications expired. This action left HBAT as the only botulinum antitoxin available in the US for naturally occurring non-infant botulism.

...
Wikipedia